CIBUS INC Stock Price, News & Analysis

Cibus (NASDAQ: CBUS), a leading agricultural biotechnology company, has completed its previously announced public offering, raising $27.5 million through the sale of 15,714,285 shares of Class A Common Stock at $1.75 per share. Notable participants included institutional and strategic investors, with the Chairman of Cibus' board of directors purchasing 5,714,286 shares. A.G.P./Alliance Global Partners served as the sole placement agent. The company plans to utilize the net proceeds to advance the development of weed management productivity traits in Rice and for working capital purposes while pursuing longer-term financing. The offering was conducted under an effective shelf registration statement filed with the SEC.

Cibus (NASDAQ: CBUS) announced that its herbicide tolerance trait (HT2) in Canola has received a 'not regulated' designation from the USDA-APHIS Biotechnology Regulatory Services. This marks Cibus' 17th trait to receive this designation, following recent approval of their disease resistance traits in Canola. The HT2 trait, developed using Cibus' Rapid Trait Development System (RTDS), aims to provide farmers with advanced weed management solutions, particularly targeting weeds resistant to commonly-used herbicides. The technology is especially significant for broad acre crops like Canola and Soybean, where weed control directly impacts crop yields. This regulatory milestone reinforces Cibus' momentum in both U.S. and international markets as they continue developing productivity and agronomic traits.

Cibus (NASDAQ: CBUS), an agricultural biotechnology company, has announced the pricing of a public offering of 15,714,285 shares of Class A Common Stock at $1.75 per share, aiming to raise approximately $27.5 million in gross proceeds. The offering includes participation from institutional and strategic investors, with the Chairman of Cibus' board of directors purchasing 5,714,286 shares. The company plans to use the proceeds to fund the development of weed management productivity traits in Rice and for working capital purposes while pursuing longer-term financing. A.G.P./Alliance Global Partners is serving as the sole placement agent, with the offering expected to close around June 6, 2025.

Cibus (NASDAQ: CBUS), an agricultural biotechnology company specializing in gene editing for plant traits in seeds, has announced a proposed public offering of Class A common stock. The company's board chairman, Rory Riggs, has expressed interest in purchasing up to $10 million of shares, though this is not a binding commitment. A.G.P./Alliance Global Partners will serve as the sole placement agent. The net proceeds will be used to fund the development of weed management productivity traits in Rice and for working capital purposes while pursuing longer-term financing. The offering will be made under an effective shelf registration statement filed with the SEC in June 2023.

Cibus (NASDAQ: CBUS), an agricultural biotechnology company specializing in proprietary gene editing technologies for seed trait development, has made available a replay of its participation in the BofA Securities 2025 AgTech Virtual Conference. During the fireside chat, Co-Founder, President and Interim CEO Peter Beetham discussed with BofA analyst Stephen Byrne three key areas: the company's unique gene editing platform, progress in their productivity trait pipeline toward commercial goals, and the impact of recent regulatory changes supporting agricultural innovation globally. The webcast recording can be accessed through Cibus's investor relations website.

Cibus (NASDAQ: CBUS), an agricultural biotechnology company specializing in proprietary gene editing technologies for seed trait development, announced its participation in the AGP Annual Virtual Healthcare Company Showcase. Peter Beetham, Co-Founder, President, and Interim CEO, will present on May 21, 2025, at 4:40 p.m. ET.

The presentation will cover three main areas: the company's progress in advancing its gene-editing technology platform, recent regulatory developments supporting agricultural innovation, and Cibus' commercialization strategy for its productivity trait pipeline.

Cibus (NASDAQ: CBUS) reported Q1 2025 financial results and business updates, highlighting significant progress in its gene editing technologies. The company reported a net loss of $49.4M ($1.34 per share), compared to $27M in the year-ago period, largely due to a $21M non-cash goodwill impairment. Cash position stands at $23.6M, expected to fund operations into Q3 2025. Key developments include: successful advancement of Rice herbicide tolerance traits (HT1 and HT3) with planned 2027 commercial launch, positive regulatory decisions in Ecuador and California, and progress in Canola disease resistance program. The company achieved positive Sclerotinia data for multiple modes of action in Canola, and received USDA-APHIS designation of Canola traits as non-regulated. EU member states endorsed regulations for New Genomic Techniques, enabling further discussions for final adoption.

Ecuador's Ministry of Agriculture and Livestock has determined that Cibus' (CBUS) herbicide tolerance Rice traits (HT1 and HT3) are equivalent to conventional breeding methods. This regulatory approval means these traits will be subject to standard seed regulations rather than strict GMO restrictions in Ecuador.

The traits, developed using Cibus' Rapid Trait Development System™ (RTDS®) technology, create targeted genetic changes without introducing foreign genetic material. Cibus plans to commercialize these traits in Latin American markets through a partnership with Interoc, focusing on providing improved weed management solutions for rice growers.

Cibus (Nasdaq: CBUS), a leading agricultural biotechnology company specializing in proprietary gene editing technologies for plant trait development in seeds, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025 after market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and company updates. Participants can join via phone using U.S. (+1-833-316-1983) or International (+1-785-838-9310) numbers with conference ID 'CIBUS' or 24287.

A replay will be available through May 22, 2025, and the webcast with slides will be accessible on the company's investor website for 90 days after the event.